{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:43:21Z","timestamp":1789699401935,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.diabres.2025.112040","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:54:09Z","timestamp":1739847249000},"page":"112040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The effect of Fluoxetine on lipid profiles in overweight or obese Individuals: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"222","author":[{"given":"Dawei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periyannan","family":"Velu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousalya","family":"Prabahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Safargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Kord-Varkaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2025.112040_b0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1092852913000667","article-title":"Metabolic syndrome and major depression","volume":"19","author":"Marazziti","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.diabres.2025.112040_b0010","unstructured":"Stuchtey, F.C., A. Block, F. Osei, and P.-M. Wippert. Lipid biomarkers in depression: does antidepressant therapy have an impact? in Healthcare. 202MDPI."},{"issue":"7","key":"10.1016\/j.diabres.2025.112040_b0015","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/npp.2014.9","article-title":"Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users","volume":"39","author":"Vogelzangs","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5152\/npa.2016.12373","article-title":"Metabolic effects of antidepressant treatment","volume":"54","author":"Eker","year":"2017","journal-title":"Archives of Neuropsychiatry"},{"issue":"3","key":"10.1016\/j.diabres.2025.112040_b0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol Int"},{"key":"10.1016\/j.diabres.2025.112040_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2832-3-2","article-title":"Fluoxetine: a review on evidence based medicine","volume":"3","author":"Rossi","year":"2004","journal-title":"Ann Gen Hosp Psychiatry"},{"issue":"4","key":"10.1016\/j.diabres.2025.112040_b0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.035","article-title":"Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China","volume":"25","author":"He","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0040","first-page":"22","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Primary care companion to the Journal of clinical psychiatry"},{"issue":"9","key":"10.1016\/j.diabres.2025.112040_b0045","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/aps.2017.207","article-title":"Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression","volume":"39","author":"Pan","year":"2018","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0050","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12872-023-03327-3","article-title":"Magnitude and associated factors of dyslipidemia among patients with severe mental illness in dire Dawa, Ethiopia: neglected public health concern","volume":"23","author":"Fentie","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.diabres.2025.112040_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1137977","article-title":"Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression","volume":"10","author":"Wu","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.diabres.2025.112040_b0060","unstructured":"Health, N.C.C.f.M., Psychosis and schizophrenia in adults: treatment and management. National Institute for Health and Care Excellence (UK), 2014."},{"issue":"8","key":"10.1016\/j.diabres.2025.112040_b0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/da.22512","article-title":"Bidirectional prospective associations of metabolic syndrome components with depression, anxiety, and antidepressant use","volume":"33","author":"Hiles","year":"2016","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.diabres.2025.112040_b0070","doi-asserted-by":"crossref","unstructured":"Viscogliosi, G., C. Donfrancesco, C. Lo Noce, S. Giampaoli, D. Vanuzzo, F. Carle, et al., Association between antidepressant medication use and prevalence and control of cardiovascular risk factors in community-dwelling older adults: The Italian health examination survey 2008\u20132012. Metabolic syndrome and related disorders, 2020. 18(2): p. 73-78.","DOI":"10.1089\/met.2019.0088"},{"issue":"10","key":"10.1016\/j.diabres.2025.112040_b0075","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1177\/0269881115592340","article-title":"Antidepressants with a high serotonin reuptake transporter affinity and serum lipid levels in a population-based study in older adults","volume":"29","author":"Noordam","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112040_b0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/j.1550-8528.1994.tb00641.x","article-title":"No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity","volume":"2","author":"Visser","year":"1994","journal-title":"Obes Res"},{"key":"10.1016\/j.diabres.2025.112040_b0085","doi-asserted-by":"crossref","unstructured":"Moher, D., A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group, Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Physical therapy, 2009. 89(9): p. 873-880.","DOI":"10.1093\/ptj\/89.9.873"},{"key":"10.1016\/j.diabres.2025.112040_b0090","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112040_b0095","unstructured":"Higgins, J., GSe. Cochrane handbook for systematic reviews of interventions version, 2011. 5(0)."},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Method"},{"issue":"7109","key":"10.1016\/j.diabres.2025.112040_b0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112040_b0110","doi-asserted-by":"crossref","unstructured":"Duval, S., The trim and fill method. Publication bias in meta-analysis: Prevention, assessment and adjustments, 2005: p. 127-144.","DOI":"10.1002\/0470870168.ch8"},{"key":"10.1016\/j.diabres.2025.112040_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2018.02.029","article-title":"Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study","volume":"168","author":"He","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0120","first-page":"90","article-title":"Effects of fluoxetine, omega 3, or their combination on serum leptin in Iraqi obese subjects","volume":"35","author":"Al-Helli","year":"2015","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"8","key":"10.1016\/j.diabres.2025.112040_b0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ijo.2013.225","article-title":"A comparative study of five centrally acting drugs on the pharmacological treatment of obesity","volume":"38","author":"Suplicy","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"6","key":"10.1016\/j.diabres.2025.112040_b0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1590\/S0004-27302006000600007","article-title":"Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients","volume":"50","author":"Guimar\u00e3es","year":"2006","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112040_b0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/j.1550-8528.1996.tb00247.x","article-title":"Usefulness of fluoxetine in obese non-insulin-dependent diabetics: A multicenter study","volume":"4","author":"Daubresse","year":"1996","journal-title":"Obes Res"},{"issue":"12","key":"10.1016\/j.diabres.2025.112040_b0140","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/0026-0495(95)90077-2","article-title":"Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity","volume":"44","author":"Breum","year":"1995","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1464-5491.1994.tb00238.x","article-title":"Fluoxetine in the treatment of obese type 2 diabetic patients","volume":"11","author":"O'Kane","year":"1994","journal-title":"Diabet Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112040_b0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1550-8528.1993.tb00597.x","article-title":"Fluoxetine: a randomized clinical trial in the maintenance of weight loss","volume":"1","author":"Goldstein","year":"1993","journal-title":"Obes Res"},{"issue":"12","key":"10.1016\/j.diabres.2025.112040_b0155","article-title":"Lipid Disorders and Cardiovascular Risk: A Comprehensive Analysis of Current Perspectives","volume":"15","author":"Wazir","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.diabres.2025.112040_b0160","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jclinpath-2021-207719","article-title":"Hypertriglyceridaemia: an update","volume":"75","author":"Wierzbicki","year":"2022","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.diabres.2025.112040_b0165","unstructured":"Giugliano, R.P., K.A. Im, M.G. Silverman, M.L. O'Donoghue, S.D. Wiviott, and M.S. Sabatine, Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. 2019."},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12872-024-04280-5","article-title":"The association between the fluoxetine use and the occurrence of coronary heart disease: a nationwide retrospective cohort study","volume":"24","author":"Li","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.diabres.2025.112040_b0175","first-page":"e41","article-title":"Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art","volume":"163","author":"Colotto","year":"2012","journal-title":"Clin Ter"},{"issue":"7","key":"10.1016\/j.diabres.2025.112040_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021551","article-title":"Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"6","author":"Ye","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.diabres.2025.112040_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103092","article-title":"Effects of the selective serotonin reuptake inhibitor fluoxetine on glucose metabolism: A systematic review","volume":"73","author":"Zhang","year":"2022","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.diabres.2025.112040_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111848","article-title":"Fluoxetine ameliorates high-fat diet-induced metabolic abnormalities partially via reduced adipose triglyceride lipase-mediated adipocyte lipolysis","volume":"141","author":"Chiu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diabres.2025.112040_b0195","article-title":"Lower baseline serum triglyceride levels are associated with higher decrease in body mass index after laparoscopy sleeve gastrectomy among obese patients","volume":"12","author":"Huang","year":"2021","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112040_b0200","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.4088\/JCP.v67n1219","article-title":"Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study","volume":"67","author":"Raeder","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.diabres.2025.112040_b0205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/JCP.0000000000000582","article-title":"Metabolic abnormalities related to treatment with selective serotonin reuptake inhibitors in patients with schizophrenia or bipolar disorder","volume":"36","author":"Fjukstad","year":"2016","journal-title":"J Clin Psychopharmacol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:23:39Z","timestamp":1763706219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"alternative-id":["S0168822725000543"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112040","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Fluoxetine on lipid profiles in overweight or obese Individuals: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112040"}}